Investors seek to back biopharma companies

Favorable policies, R&D raise visions of a 654 billion yuan market by 2030

Biopharmaceutical companies in China are receiving heightened investor attention of late, experts said.

"China's evolving regulatory policies and enhanced business environment have certainly led to a boom in the R&D (research and development) activity relating to new medicines. Investors have noticed the trend and are rushing to the market," said Han Tao, deputy general manager of China Capital Investment Group, at an event.